Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rifaquat Musaffa Rahman, M.D.

Concepts

This page shows the publications Rifaquat Rahman has written about Humans.
Connection Strength

0.099
  1. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304.
    View in: PubMed
    Score: 0.011
  2. Neurologic Complications of Cranial Radiation Therapy and Strategies to Prevent or Reduce Radiation Toxicity. Curr Neurol Neurosci Rep. 2020 06 29; 20(8):34.
    View in: PubMed
    Score: 0.011
  3. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.
    View in: PubMed
    Score: 0.011
  4. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. Clin Cancer Res. 2019 11 01; 25(21):6339-6345.
    View in: PubMed
    Score: 0.010
  5. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. J Neurooncol. 2018 Jun; 138(2):299-306.
    View in: PubMed
    Score: 0.009
  6. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
    View in: PubMed
    Score: 0.008
  7. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
    View in: PubMed
    Score: 0.007
  8. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58.
    View in: PubMed
    Score: 0.007
  9. The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801.
    View in: PubMed
    Score: 0.003
  10. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Eur Radiol. 2021 Jun; 31(6):4114-4129.
    View in: PubMed
    Score: 0.003
  11. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249.
    View in: PubMed
    Score: 0.003
  12. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
    View in: PubMed
    Score: 0.002
  13. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043.
    View in: PubMed
    Score: 0.002
  14. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697.
    View in: PubMed
    Score: 0.002
  15. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687.
    View in: PubMed
    Score: 0.002
  16. Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients. Eur J Radiol. 2016 Mar; 85(3):657-64.
    View in: PubMed
    Score: 0.002
  17. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81.
    View in: PubMed
    Score: 0.002
  18. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma. J Neurooncol. 2014 Aug; 119(1):111-9.
    View in: PubMed
    Score: 0.002
  19. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88.
    View in: PubMed
    Score: 0.002
  20. fMRI BOLD response of high-risk college students (Part 2): during memory priming of alcohol, marijuana and polydrug picture cues. Alcohol Alcohol. 2010 Sep-Oct; 45(5):444-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.